[Epidemiological and clinical study for hepatitis C virus infection].
Hayashi
Jun
J
Department of Medicine and Surgery, Internal Medicine, Environmental Medicine and Infections Diseases, Faculty of Medical Sciences, Kyushu University.
Furusyo
Norihiro
N
D000998:Antiviral Agents / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D015490:HTLV-I Infections; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy / Q000453:epidemiology* / Q000635:transmission / Q000821:virology; D006801:Humans; D007333:Insulin Resistance; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007564:Japan / Q000453:epidemiology; D008113:Liver Neoplasms / Q000821:virology; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects; D012254:Ribavirin / Q000008:administration & dosage
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b